Cheetah Medical Introduces Noninvasive Monitoring System

Cheetah Medical Introduces Noninvasive Monitoring System

Demand for noninvasive hemodynamic monitoring devices fueling company’s growth.

Cheetah Medical recently introduced the U.S. Food and Drug Administration (FDA)-cleared and CE-marked Starling SV, a noninvasive hemodynamic monitoring system that provides data for real-time clinical decision-making and better patient outcomes across a hospital’s continuum of care.

Dynamic IV fluid-assessment using the new Starling SV and the Cheetah Nicom systems can help clinicians determine non-invasively and in real time whether patients will benefit or potentially be harmed by additional IV fluids.

“No matter the site of care or the clinical challenge, effective hemodynamic measurement and management is integral to achieving an optimal clinical outcome,” said Douglas Hansell, M.D., chief physician executive for Cheetah Medical. “Approximately 50 percent of hospitalized patients are at risk of hemodynamic overload.2 Until the introduction of Cheetah Nicom, the only choices for obtaining accurate and continuous hemodynamic measurements were invasive technologies that carry their own set of risks. Now, with the Starling SV or Cheetah Nicom, a clinician has all of the important parameters continuously at his or her disposal. Clinical status and the effect of IV fluids can be monitored at any time and treatment modified accordingly.”

The expansion of Cheetah Medical’s product line occurs in the wake of three major clinical trial results (ProCESS, ProMISE, Arise), as well as updated sepsis guidelines by Surviving Sepsis Campaign, National Quality Forum, Centers for Medicare & Medicaid Services, and European Society of Intensive Care Medicine (ESICM)3,4,5— all of which updated their guidance to include dynamic measures of fluid responsiveness for patients with severe sepsis or septic shock.

Intravenous fluid responsiveness also is a major component of enhanced recovery after surgery, which now shows improved clinical outcomes for surgical patients. “The FDA-cleared and CE-marked Cheetah hemodynamic monitoring systems are designed and positioned as the solution for completely noninvasive and continuous IV-fluid assessment in the operating room or a critical care setting,” said Chris Hutchison, president/CEO of Cheetah Medical.

The Starling SV system has a sensitivity of 94 percent and specificity of 100 percent for predicting IV-fluids responsiveness in critical care situations6. The noninvasive Starling SV system predicts IV-fluids responsiveness similarly to invasive esophageal Doppler and other invasive modalities5. In addition to predicting fluid responsiveness, Starling SV is one of the few technologies that allows clinicians to directly monitor the change in cardiac stroke volume with therapy, company executives claim. Starling SV may assist in reducing hospital length of stay7.

Starling SV Benefits Summarized:

  • 100 percent noninvasive, easy to use, with no patient discomfort.
  • Eliminates risk of infection and vascular damage associated with older, invasive technologies requiring arterial or central lines.
  • Independently validated against pulmonary artery catheter.
  • Accuracy not affected by vasopressors, inotropes, and shock states.
  • Nurse driven.
  • EMR-compatible, with the ability to establish a time-stamped patient record for documentation.
  • Provides continuous information on Cardiac Index, Cardiac Output, StrokeVolume Index, Stroke Volume, Total Peripheral Resistance, and other vitally important parameters.

Based in Newton Center, Mass., Cheetah Medical develops noninvasive hemodynamic monitoring technology. The company was founded in 2001 in Tel Aviv, Israel, with the mission of helping clinicians manage their patient’s fluid status. 


1 The global hemodynamic monitoring systems market is expected to reach $1.1074 billion by 2019, according to MarketsandMarkets; Cheetah’s growth currently exceeds the CAGR of 4.5% forecast for the same period.

2 Marik PE, et al. Hemodynamic parameters to guide fluid therapy. Ann of Intensive Care 2011; 1:1.



5 Cecconi M, Backer DD, et al. Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine. 2014

6 Marik PE, et al. Chest, 2013.

7 Dunham et al. J Trauma Acute Care Surg, 2012

Learn more about Cheetah Medical's technology in the video below:

Related Searches:
Suggested For You

Related Videos